非维生素K拮抗剂口服抗凝药患者缺血性卒中再灌注溶栓治疗:II期随机临床试验研究方案
本研究为II期前瞻性随机安慰剂对照试验,纳入长期服用Xa因子抑制剂(利伐沙班或阿哌沙班)的急性缺血性卒中患者,先给予特异性逆转剂(andexanet alfa)或安慰剂,再行rtPA或安慰剂静脉溶栓,评估逆转后溶栓的可行性、疗效与安全性。
要点
- 房颤患者口服抗凝治疗可降低AIS风险超80%,但仍有部分患者发生卒中。
- 约半数口服抗凝房颤患者发生AIS后不符合溶栓或取栓标准。
- 本研究探索Xa因子抑制剂逆转后rtPA溶栓的可行性、疗效与安全性。
核心结论
- STROACT试验是首个在Xa因子抑制剂相关AIS患者中探索逆转后静脉溶栓的随机II期研究,结果旨在产生假设并指导未来确证性试验设计。
研究设计与样本
- 前瞻性、随机、安慰剂对照II期干预性试验,针对利伐沙班和阿哌沙班分别设计研究臂。
- 纳入长期服用具有抗Xa活性的特定口服抗凝药(DOAC)的急性缺血性卒中患者。
关键数值与推荐
- 口服抗凝治疗可使房颤患者AIS风险降低超过80%。
- 约半数口服抗凝房颤患者发生AIS后不符合溶栓(OAC血活性高)或机械取栓(非大血管闭塞卒中)标准。
- 干预措施:先给予andexanet alfa(针对利伐沙班或阿哌沙班)或安慰剂,随后给予rtPA或安慰剂静脉溶栓。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardioembolic stroke accounts for more than 20% of all acute ischemic strokes (AIS) and is mainly caused by cardiac arrhythmias, particularly atrial fibrillation (AF). The presence of specific or multiple additional vascular risk factors indicates the need for oral anticoagulant (OAC) therapy in AF patients (according to the CHA2DS2-VASc classification). While OAC treatment significantly reduces the risk of AIS by over 80% in this population, the risk remains higher compared to the general population. Approximately half of AF patients on OAC therapy who experience AIS do not meet the criteria for thrombolytic (high blood activity of OAC) or mechanical thrombectomy (non-large vessel occlusion stroke) treatment. AIM: This study aims to assess the efficacy and safety of recombinant tissue plasminogen activator (rtPA) in AIS patients who have been on chronic non-vitamin K antagonist oral anticoagulant (DOAC) therapy after receiving a specific reversal agent. METHODS AND DESIGN: Patients with acute ischemic stroke (AIS) who are treated with specific oral anticoagulants (OACs) with anti-Xa activity have been on chronic non-vitamin K antagonist oral anticoagulant e included in the study. The protocol involves administering a fast-acting antidote (andexanet alfa for rivaroxaban or apixaban) or a placebo, followed by intravenous thrombolytic therapy with rtPA or a placebo. The study arms for rivaroxaban and apixaban are designed as prospective, randomized, placebo-controlled interventional trials that meet phase II trial criteria. DISCUSSION: The STRoke on Oral AntiCoagulants for Thrombolysis (STROACT) trial is, to our knowledge, the first randomized phase II study designed to explore the feasibility, efficacy, and safety of reversal-enabled intravenous thrombolysis in a highly selected population of acute ischemic stroke patients on factor Xa inhibitors. The results are expected to be hypothesis-generating and may inform the design of future confirmatory trials. TRIAL REGISTRATION: www.clinicaltrialsregister.eu ; EudraCT Nr: 2020-004898-41; March 31, 2021.
引用
- Karaszewski B, Jabłoński B, Gąsecki D, et al. Reperfusion thrombolytic therapy for ischemic stroke in patients on non-vitamin K antagonist oral anticoagulants: study protocol of a phase II randomized clinical trial. Trials. 2026. PMID: 42093017. doi:10.1186/s13063-026-09699-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。